Relevance on the diagnosis of malignant lymphoma of the salivary gland

Xin-Yue Zhang, Zhi-Ming Wang

ORCID number: Xin-Yue Zhang 0000-0001-9773-7137; Zhi-Ming Wang 0000-0002-2381-2461.

Author contributions: Zhang XY contributed to the majority of the writing; Wang ZM performed the Table and edited the article.

Supported by the 345 Talent Project of Shengjing Hospital; and the Natural Science Foundation of Liaoning Province, No. 20170541042.

Conflict-of-interest statement: No potential conflicts of interest. No financial support.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Invited manuscript

Abstract

Malignant lymphoma originates from the lymphohematopoietic system. It can occur in any lymphoid tissue. Malignant lymphoma of the salivary gland is rare, but its incidence has increased in recent years. Its clinical presentations are non-specific, and it is often manifested as a painless mass in a salivary gland, which can be accompanied by multiple swollen cervical lymph nodes. Confirmation of the diagnosis before an invasive procedure is difficult. Clinically, malignant lymphoma of the salivary gland tends to be misdiagnosed, leading to an inappropriate treatment plan and the ultimate delay in the optimal treatment of the disease. This article reviews the pathogenesis, clinical features, imaging findings, diagnosis, treatment and prognosis of malignant lymphoma of the salivary gland.

Key words: Salivary gland; Malignant lymphoma; Pathogenic factors; Clinical features; Diagnosis; Treatment

©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Salivary gland lymphoma (SGL) is rare, and it is often manifested as a painless mass in a salivary gland, with or without multiple swollen cervical lymph nodes. Clinically, SGL tends to be misdiagnosed as other epithelial tumors of the salivary gland, leading to an inappropriate surgical excision and delay in the optimal treatment of the disease. This article reviews the pathogenesis, clinical features, imaging findings, diagnosis, treatment and prognosis of SGL.

Citation: Zhang XY, Wang ZM. Relevance on the diagnosis of malignant lymphoma of the salivary gland. World J Clin Cases 2020; 8(13): 2717-2726
INTRODUCTION

Lymphoma is a malignant tumor originating from the lymphohematopoietic system. It is a group of diseases with extensive clinical and histological features, genetic abnormalities, and immunophenotypes. Lymphomas account for 3%-4% of malignant tumors and is the most common head and neck malignancy after squamous cell carcinoma and thyroid cancer\(^5\). Lymphoma can be divided into two major histopathological entities, Hodgkin lymphoma (HL) and non-HL (NHL), and can be subdivided into intranodal and extranodal types according to its origination inside or outside a lymph node. The majority of oral and maxillofacial lymphomas are extranodal NHLs\(^6\). Head-and-neck NHLs can originate in any lymphoid tissue, most commonly in Waldeyer's ring, the nasal cavity, nasal sinuses, oral cavity, and salivary glands\(^7\). An NHL originating from a salivary gland is rare, accounting for only 1.7%-3.1% of all salivary gland malignant tumors\(^8\). Most NHLs involving the salivary glands originate from B cells, with the most common location being the parotid glands, followed by the submandibular glands, minor salivary glands, and sublingual glands, in descending order\(^9\). Salivary gland lymphoma (SGL) is a diverse tumor with nonspecific clinical features and imaging manifestations. Therefore, differentiating it from other epithelial tumors of the salivary gland is difficult.

Because of the complicated histopathological classification of NHLs, the gold standard for the diagnosis and determination of the subtype of this disease is an incisional biopsy of the deep portion of tumor\(^10\). The complexity of the diagnostic process can lead to a misdiagnosis or a delayed diagnosis\(^11\). Because the treatment for SGL is different from the treatment for an epithelial tumor of the salivary gland and lymphomas in other parts, a misdiagnosis or delayed diagnosis may lead to an inappropriate treatment plan, affecting the outcome of the patients.

A primary SGL is thought to involve the parenchyma of the salivary gland, rather than being confined to soft tissue or a regional lymph node, and no lymphomatous lesion was detected in other parts of the body before diagnosis\(^12\). In view of the diagnostic difficulties for primary salivary gland lymphomas, we researched 944 articles about malignant lymphoma of the salivary gland published in PubMed from 2000 to December 2019 in English. Some of the articles were excluded because they were not primarily originated from the salivary gland tissue. Among them, 344 articles involved the research on the primary salivary gland lymphoma, including 102 case reports. In addition, the data from articles other than case reports was not concrete concerning the clinical information, so we finally selected 16 case reports, and the detailed data are listed in Table 1\(^13\). This article analyzes the pathogenesis, clinical features, imaging findings, diagnosis, treatment, and prognosis of primary SGL.

PATHOGENETIC FACTORS

The incidence of SGL has recently shown an upward trend. Epidemiological investigations show that the main causative factors of malignant lymphoma include infection and changes in immune function. Genetic factors, occupational and environmental factors, diet, smoking, alcohol, and socioeconomic status are also involved.

Viral infections

The prevalence of NHL in human immunodeficiency virus (HIV)-infected people is almost twice that in the general population\(^12\). HIV infection is believed to be associated with lymphomagenesis primarily due to the immunosuppressed state of the patient rather than mechanisms involving the virus per se\(^13\). The development of AIDS-related NHL is caused by long-term administration of HIV-related immunostimulant leading to the proliferation of B lymphocytes\(^12\). The parotid gland is the most common location of SGL in HIV patients\(^14\).

Epstein-Barr virus (EBV) is associated with a variety of malignant lymphomas, including Burkitt lymphoma, HL, and BHL\(^15\). EBV is a herpes virus that can infect B and T lymphocytes, natural killer cells, epithelial cells, and myocytes\(^16\). Antibodies
Table 1 Clinical features of cases with lymphoma of the salivary gland

| Ref.          | Age/sex | Location                  | Size(mm) | Pathogenic type | Treatment                        | Response | Follow-up |
|---------------|---------|---------------------------|----------|-----------------|----------------------------------|----------|-----------|
| Andola et al. | 55/M    | Bilateral parotid         | 50 × 40  | DLBCL           | Radiation therapy + chemotherapy | CR       | 1 yr      |
| Hwang et al.  | 56/F    | Parotid                   | 25 × 8   | MALT            | Chemotherapy                     | CR       | 6 mo      |
| Shum et al.   | 53/F    | Parotid                   | 15 × 12  | MALT            | Radiation therapy                | CR       | 5 yr      |
|               | 53/F    | Parotid                   | 21 × 9   | FL              | Chemotherapy                     | CR       | 2 yr      |
|               | 63/F    | Parotid                   | 20 × 80  | FL              | Chemotherapy + radiation therapy | CR       | 1 yr      |
| Choi et al.   | 16/M    | Parotid                   | 35 × 20  | FL              | Radiation therapy                | CR       | 6 mo      |
| Alnoor et al. | 69/M    | Parotid                   | 25 × 8   | MALT            | Chemotherapy                     | CR       | 3 mo      |
| Park et al.   | 68/F    | Parotid                   | NA       | FL              | Radiation therapy + chemotherapy | CR       | NA        |
|               | 55/M    | Parotid                   | NA       | FL              | Radiation therapy                | RD       | 54 mo     |
| Yang et al.   | 41/M    | Parotid                   | NA       | MALT            | Radiation therapy + chemotherapy | RD       | 12 mo     |
| Yenal-Hindilerden et al. | 61/F | Ulcerated palate + parotid | 20 × 25/25 × 35 | MALT | Chemotherapy (R-CHOP) | CR | 44 mo |
| Shashidara et al. | 40/F | Submandibular            | 90 × 40  | FL              | NA                               | NA       | NA        |
| Faur et al.   | 71/F    | Parotid                   | 50 × 35  | DLBCL           | NA                               | NA       | NA        |
|               | 49/F    | Parotid                   | 65 × 63  | MALT            | NA                               | NA       | NA        |
| Alves et al.  | 32/M    | Parotid                   | 30       | NLPHL           | Radiation therapy                | CR       | 1 yr      |
| Revanappa et al. | 73/F | Parotid + submandibula  | NA       | DLBCL           | Radiation therapy + chemotherapy | NA | NA        |
| Titişinides et al. | 64/F | Ulcerated palate + submandibula | 10 | MALT | Chemotherapy | CR | 2 yr |
| Van Mello et al. | 53/F | Labial + parotid         | NA       | MALT            | Chemotherapy                     | NA       | NA        |
|               | 55/F    | Labial + parotid          | NA       | MALT            | Chemotherapy                     | NA       | NA        |
| Hew et al.    | 55/F    | Parotid                   | 20 × 8   | T cell lymphoma | Radiation therapy + chemotherapy | NA | NA |

MALT: Mucosa associated lymphoid tissue lymphoma; DLBCL: Diffuse large B cell lymphoma; FL: Follicular lymphoma; CR: Complete remission; NA: Not available; RD: Relapsed disease; R-CHOP: Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone; NLPHL: Nodular lymphocyte predominance hodgkin lymphoma.

EBV-related NHLs are more common in immunosuppressed populations, especially those infected with HIV [36,38]. Many epidemiological studies have provided evidence that hepatitis C virus (HCV) infection is associated with the development of indolent and aggressive B-cell lymphomas [39-41]. HCV-infected patients may develop lymphomas that are either independent of viral infection or result from indirect activation of B cells by the virus [42]. Investigators have proposed several mechanisms for HCV-induced lymphomagenesis. These mainly include the chronic viral stimulation of lymphocytes and HCV replication in B cells, which is mediated by the interaction of HCV envelope proteins with lymphocyte-specific glycoproteins [42-44].

**Helicobacter pylori infection**

Mucosa-associated lymphoid tissue (MALT) lymphoma is an extranodal marginal-
Zhang XY et al. Malignant lymphoma/salivary gland

zone B-cell lymphoma\textsuperscript{[38]}, and is the third most common subtype of NHL after diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). It exhibits an indolent behavior\textsuperscript{[46,47]}. Although gastric MALT is most common, it can develop in almost every organ and tissue, including the salivary gland, thyroid gland, thymus, skin, and orbital adnexa\textsuperscript{[48-50]}. Helicobacter pylori (H. pylori) infection is thought to play a key role in the development of gastric MALT lymphoma\textsuperscript{[51-53]}. Normal gastric mucosa and salivary glands do not contain lymphoid tissue, but the long-term exposure to microbial antigens in a chronic inflammatory disease can lead to increased lymphoid tissue\textsuperscript{[54,55]}. Similar to gastric MALT, chronic gastritis associated with H. pylori infection confers a significantly increased risk of SGL\textsuperscript{[56,57]}.  

**Immunosuppression**  
Factors associated with immunosuppression are linked with an increased risk of lymphoid malignancies\textsuperscript{[58,59]}. Primary or secondary immunosuppression and autoimmune are associated with NHLs\textsuperscript{[60-62]}. Autoimmune conditions have attracted substantial attention; Sjögren syndrome (SS), systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and immunosuppressive therapy for solid organ or stem cell transplantation are frequently associated with increased risk of NHL\textsuperscript{[63,64]}.  

SS is characterized by lymphocytic infiltration and destruction primarily of salivary and lacrimal glands, which leads to xerostomia and xerophthalmia, respectively. Among the salivary glands, the parotid and submandibular glands are primarily affected\textsuperscript{[58,59]}. According to a meta-analysis of 20 studies, SS presents a higher risk factor for development of NHL than SLE and RA\textsuperscript{[58,59]}. The main risk factor for death in patients with SS is thought to be lymphoma\textsuperscript{[58,59]}. There is evidence that the occurrence of lymphoma in SS patients is related to ectopic germinal center-like structures in salivary gland biopsy tissue\textsuperscript{[59]}. Moreover, the structures are connected with elevated levels of numerous chemokines, including C-X-C motif chemokine ligand 13 and C-C motif chemokine ligand 11, the levels of which were significantly elevated in patients with SS-associated SGL\textsuperscript{[59,60,61]}.  

**CLINICAL FEATURES AND PRESENTATIONS**  
Clinical presentations of SGL are nonspecific\textsuperscript{[62,63]}, so that a routine clinical examination cannot differentiate them from other benign or malignant salivary gland tumors\textsuperscript{[64]}. The disease affects both genders equally. The mean age of patients is generally older than 50 years\textsuperscript{[64]}. Patients with primary lymphoma of the parotid gland generally present with a unilateral asymptomatic mass that enlarges over a period of time. Other manifestations include bilateral swelling of the parotids, cervical lymphadenopathy, pain, and facial nerve paralysis\textsuperscript{[33,56-60]}. The tumor appears as a border-clear, medium-texture mass, and even presents with superficial ulcers when inflammation is present\textsuperscript{[60]}. Lymphomas occasionally cause diffuse swelling of parotid gland region similar to mumps\textsuperscript{[60]}. Unilateral or bilateral glands may present enlargement if lymphomas occur in the submandibular glands, with hypoglossal nerve and mandibular margin branches of the facial nerve being rarely involved\textsuperscript{[56-58]}. The most frequent location of lymphomas of the minor salivary glands is the hard palate\textsuperscript{[68]}. They can initially appear as a nontender diffuse mass protruding from the mucosal surface, and are sometimes accompanied by ulceration and pain\textsuperscript{[56,69]}. NHL occurring in the sublingual glands is extremely rare. It can be manifested as a diffuse swelling of the floor of the mouth with indistinct boundaries, and is easily misdiagnosed as a cyst of the sublingual gland\textsuperscript{[69]}.  

**IMAGING MANIFESTATIONS**  
Lymphomas of the parotid glands are more common than SGL. Therefore, we reviewed the imaging characteristics of lymphomas of the parotid glands and synthesized information from the literature. The initial evaluation for a mass involving the parotid gland should include ultrasound, computed tomography (CT), or magnetic resonance imaging (MRI) to determine the location, shape, size, and intensity of the mass. The literature indicates that the CT and MRI findings of MALT lymphoma of the parotid gland include variations in the contours and internal structures of the masses, as follows: Solitary solid mass, solitary solid-cystic mass, diffusely solid-cystic lesion, and multiple solid nodules or masses, in which solitary and diffusely solid-cystic
changes are more common\(^{70,71}\). Non-MALT lymphomas of the parotid gland are characterized mainly as solitary lesions, usually accompanied by enlarged and fused cervical lymph nodes. They are also characterized as well-defined masses of uniform density with necrotic areas within the tumor matrix\(^{45,46}\). MRI features of lymphomas of the parotid gland generally include masses with homogeneous intermediate-signal intensity and an enhancing rim on the postcontrast T\(_2\)-weighted images and low-signal intensity on the T\(_2\)-weighted images without obvious enhancement effects\(^{46,47}\).

**HISTOPATHOLOGY AND CLINICAL STAGES OF SGL**

The definitive histopathological diagnosis and final classification of malignant lymphomas depend on histopathological examinations combined with immunohistochemical staining. B cell non-Hodgkin's SGL is predominant, it can be of any histopathological classification, though\(^{30,31}\). The common subtypes of lymphomas of the salivary glands include MALT lymphoma, DLBCL, and FL. T-cell types and HL are rare\(^{31}\). Based on the natural course of the disease, SGL can also be divided into aggressive and indolent types, among which DLBCL is aggressive and MALT lymphoma and FL are indolent\(^{46,47}\). Clinical staging is generally determined according to the Ann Arbor staging system, and is aided by Positron emission tomography-CT (PET-CT) and the evaluation of a bone marrow biopsy\(^{13,72}\).

**DIAGNOSTIC APPROACHES**

Attention should be paid to the differential diagnosis of a SGL when the rapidly growing, painless mass occurs in a salivary gland, and especially if multiple cervical lymph nodes are involved. Imaging studies can indicate whether or not the mass involves a salivary gland but do not aid in the histological classification\(^{31}\). The gold standard for diagnosis is histopathological examination of a specimen combined with immunohistochemical staining\(^{45,46}\).

Fine needle aspiration cytology (FNAC) has recently become the method of choice for salivary gland tumors, because an FNA is safe, easy-to-perform, quick, repeatable, and without risk of seeding tumors along the needle tract. Data from the literature indicates that the overall sensitivity, specificity, and accuracy of FNAC for lesions of the oral cavity and salivary glands are 89.5%, 100%, and 85%, respectively\(^{73}\). Since FNAC provides morphological findings on individual and small group of cells aspirated by a fine needle\(^{74}\), it can lead to a false-negative diagnosis of lymphoma. Fakhry et al\(^{75}\) studied the diagnostic value of FNAC for 249 parotid tumors and obtained false-negative results for 11 cases (7.7%), among which lymphoma was the most common histological type. The high false-negative diagnostic rate of FNAC for lymphoma is due to the low sensitivity of FNAC, particularly for cystic tumors and/or tumors situated deep in salivary gland parenchyma. The review of the literature revealed that the diagnostic accuracy of FNA is affected by both the inadequate cellularity of the smears and inadequate sampling of the lesions\(^{75}\). In addition, morphological analysis is a difficult method for accurate identification of the histological subtypes of NHL of the salivary gland\(^{11,74}\). In conclusion, an excisional biopsy of the lesion is the most important approach for the diagnosis of SGL.

In addition, \(^{18}\)F-fluorodeoxyglucose (\(^{18}\)F-FDG) PET/CT is an important noninvasive means for the diagnosis and staging of NHLs\(^{77}\). It provides both structural and functional metabolic information while localizing and estimating the tumor burden\(^{79}\). The diagnostic accuracy of \(^{18}\)F-FDG PET/CT depends on the avidity of tumors for \(^{18}\)F-FDG, which varies for different histological subtypes, regardless of grade\(^{72,79}\). The literature review revealed that invasive lymphoma subtypes have high \(^{18}\)F-FDG avidity; therefore, \(^{18}\)F-FDG PET/CT is the current reference standard for the staging of invasive lymphomas\(^{72,79}\). By contrast, the sensitivity of \(^{18}\)F-FDG PET/CT for indolent lymphomas is not high\(^{72,79,80}\). Since \(^{18}\)F-FDG PET/CT leads to a substantial dose of ionizing radiation, whole-body (WB)-MRI has been proposed as the radiation-free imaging technique of choice for the staging of indolent lymphomas with low \(^{18}\)F-FDG avidity\(^{79}\). Even so, \(^{18}\)F-FDG PET/CT remains the reference standard for the staging of HL and invasive NHL. WB-MRI tends to underestimate the response of the tumor to treatment. Multicenter prospective studies are needed to further confirm the role of WB-MRI in staging SGL\(^{80,79}\).

Small clonal B-cell populations, which is also known as monoclonal B-cell lymphocytosis, has been found to be associated with occult SGL. However, the
evaluation of monoclonal B-cell lymphocytosis in bone marrow has been mainly used for staging the lymphoma or monitoring the response to treatment.[80]

**TREATMENT AND PROGNOSIS**

The treatment of SGL depends on the histopathological classification of the lesion, which leads to an individualized treatment plan. The treatment is generally nonsurgical, depending mainly on chemotherapy, radiation, or both.[15] Aggressive lymphomas such as DLBCL of the salivary gland are presumed to be disseminated disease. The suggested treatment is systemic chemotherapy and rituximab.[15] The standard treatment of DLBCL is rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP).[81] However, there remains room for improvement, particularly for elderly patients and patients with advanced or recurrent DLBCL.[83] Wilson et al.[83] studied the regimen consisting of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin plus rituximab (R-DA-EPOCH), which might be better than R-CHOP.

FL and MALT are two common subtypes of indolent NHL of the salivary glands. Radiotherapy is often applied for the treatment for indolent NHL of the salivary glands, and the standard dose range is normally between 20 and 30 Gy.[84] 24 Gy is the curative dose for early stages of MALT, which could minimize toxicity.[85] But anti-infection treatment is required if the MALT is associated with *H. pylori* infection.[86,87] A watch-and-wait approach is often recommended by the treatment guidelines for patients with low-grade FL of the salivary glands who are asymptomatic at the time of diagnosis.[88] In patients with advanced indolent lymphomas including MALT and FL, bendamustine plus rituximab (BR) can be considered as a preferred first-line treatment regimen over R-CHOP.[88,89] However, FL can transform into DLBCL, and is expected to behave more like DLBCL. Therefore, the World Health Organization classification recommends that FL should be treated with the same regimen that is used for DLBCL.[88] For recurrent and refractory indolent or aggressive lymphomas, autologous hematopoietic stem-cell transplantation is usually used in combination with high-dose chemotherapy.[89]

The evaluations of response include complete remission (CR), partial remission (PR), and progression of disease (PD). CR has been defined as the complete disappearance of signs and symptoms due to lymphoma for at least 6 wk. PR has been defined as a reduction of at least 50% of the product of the largest perpendicular diameters of all measurable lesions for a duration of at least 6 wk. PD has been defined as clear evidence of advancing disease, despite continuation of the treatment.[90] WB metabolic tumor volume (MTV) is a new metric derived from 18F-FDG PET/CT to predict response to therapy and outcomes in patients with lymphomas, especially aggressive NHL. MTV is a volume parameter that can be quantitatively measured. The most common method to measure MTV is the fixed threshold method, where the optimal threshold is standard uptake value (SUV) 3 or SUV 6. The risk of disease progression increases with higher value of MTV.[92]

**CONCLUSION**

Primary SGL with or without cervical masses is an uncommon tumor. Most lymphomas of the salivary gland are B-cell NHLs, including mainly MALT, DLBCL, and FL. The gold standard for diagnosis is the excisional biopsy combined with histopathological examination and immunohistochemical staining. The optimal treatment is chemotherapy or radiotherapy instead of complete surgical excision. At present, R-DA-EPOCH and BR have been widely recommended. The overall survival rate for patients with NHL of the salivary gland is usually higher than for patients with lymphomas originating from other extranodal sites. The prognosis of patients with lymphomas involving the salivary glands depends on the pathological subtypes and staging. Generally, patients with MALT and FL have a much better prognosis than patients with DLBCL. 18F-FDG PET/CT is frequently used for monitoring the patients during the post-treatment period. Regular follow-ups could improve the survival rates of patients with SGL.
REFERENCES

1. Weber AL, Rahemtullah A, Ferry JA. Hodgkin and non-Hodgkin lymphoma of the head and neck: clinical, pathologic, and imaging evaluation. *Neuroimaging Clin N Am* 2003; 13: 371-392 [PMID: 14631860 DOI: 10.1016/s1052-5149(03)00039-x]

2. Vega F, Lin P, Medeiros LJ. Extranasal lymphomas of the head and neck. *Ann Diagn Pathol* 2005; 9: 340-350 [PMID: 16308165 DOI: 10.1016/j.jamdiapath.2005.09.020]

3. Stork C, Brandstetter M, Keller U, Knopf A. Clinical presentation and characteristics of lymphomas in the head and neck region. *Head Face Med* 2019; 15: 1 [PMID: 30660206 DOI: 10.1186/s13001-018-0186-0]

4. Cooper JS, Porter K, Mallin K, Hoffman HT, Weber RS, Ang KG, Guy EG, Langer CJ. National Cancer Database report on cancer of the head and neck: 10-year update. *Head Neck* 2009; 31: 748-758 [PMID: 19189340 DOI: 10.1002/hed.21022]

5. Torjussen W, Holt GL. [Non-Hodgkin lymphoma in the head and neck region]. *Tidskr Nor Laegeforen* 2002; 122: 1098-1100 [PMID: 12083157]

6. Salplatha D, Comănescu MV, Anghelina F, Ionăş I, Mogoştană C, Anghelina L. Non-Hodgkin lymphomas of Waldeyer's ring. *Rom J Morphol Embryol* 2012; 53: 1057-1060 [PMID: 23303032]

7. Raut A, Huryn J, Pollack A, Zlotolow I. Unusual gingival presentation of post-transplantation lymphoproliferative disorder: a case report and review of the literature. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2000; 90: 436-441 [PMID: 11027379 DOI: 10.1067/moe.2000.107446]

8. Jamal B. Treatment of Parotid Non-Hodgkin Lymphoma: A Meta-Analysis. *J Glob Oncol* 2018; 4: 1-6 [PMID: 30241443 DOI: 10.1097/JGO.0000000000000071]

9. Wolvius ER, van der Valk P, van der Wal JE, van Diest PJ, Huijgens PC, van der Waal I, Snow GB. Primary non-Hodgkin’s lymphoma of the salivary glands. An analysis of 22 cases. *J Oral Pathol Med* 1996; 25: 177-181 [PMID: 8980660 DOI: 10.1111/j.1600-0714.1996.tb00216.x]

10. Etemad-Moghadam S, Tigrany F, Keshavarz S, Alaeddini M. Head and neck non-Hodgkin’s lymphoma: a 20-year demographic study of 381 cases. *Int J Oral Maxillofac Surg* 2010; 39: 869-872 [PMID: 20538427 DOI: 10.1016/j.ijom.2010.03.029]

11. Dunn P, Kuo TT, Shih LY, Lin TL, Wang PN, Kao MC, Tang CC. Primary salivary gland lymphoma: a clinicopathological study of 23 cases in Taiwan. *Acta Haematol* 2004; 112: 203-208 [PMID: 15564732 DOI: 10.1159/0000841273]

12. Neerupakam M, Prakash J, Koduri S, Vishnubhatla T. Non-Hodgkin’s lymphoma of the mandible in HIV patient - A Rare Case Report. *Contemp Clin Dent* 2018; 9: 110-113 [PMID: 29595955 DOI: 10.4103/ccd.ccd_543_17]

13. Andola SK, Masgal MM, Reddy RM. Diffuse large B-cell lymphoma of the parotid gland: Cytological, histopathological, and immunohistochemical features: A rare case report. *J Cytol* 2016; 33: 226-228 [PMID: 28028346 DOI: 10.1007/s13105-016-0144-1]

14. Hwang JH, Kim DW, Kim KS, Lee SY. Mucosa-associated lymphoid tissue lymphoma of the accessory parotid gland presenting as a simple mass check: A case report. *Medicine (Baltimore)* 2019; 98: e17042 [PMID: 31490935 DOI: 10.1097/MED.00000000000017042]

15. Shum JW, Emmerling M, Lubek JE, Ord RA. Parotid lymphoma: a review of clinical presentation and management. *Oral Surg Oral Med Oral Pathol Oral Radiol* 2014; 118: e1-e5 [PMID: 24405648 DOI: 10.1016/j.ooos.2013.10.013]

16. Choi J, Choi HJ, Yim K, Kwon H, Byeon JH, Jung SN. Pediatric follicular lymphoma of the parotid gland. *J Oral Maxillofac Surg* 2018; 19: 279-282 [PMID: 30613990 DOI: 10.7181/acs.2018.02075]

17. Alnoor F, Gandhi JS, Stein MK, Gradowski JF. Follicular Lymphoma Diagnosed in Warthin Tumor: A Case Report and Review of the Literature. *J Oncol* 2018; 97: 1-6 [PMID: 28028346 DOI: 10.1007/s12105-019-01045-x]

18. Romero M, González-Fontal GR, Duarte M, Saavedra C, Hueno-Martínez AF. Small clonal B-cell population in the bone marrow as a possible tool in the diagnosis of occult primary parotid lymphoma. *Colomb Med (Cali)* 2016; 47: 59-62 [PMID: 27226666]

19. Park CK, Manning JT Jr, Baittoria H, Medeiros LJ. Follicle center lymphoma and Warthin tumor involving the same anatomic site. Report of two cases and review of the literature. *Am J Clin Pathol* 2000; 113: 113-119 [PMID: 10631864 DOI: 10.1093/ajcp/113.1.113]

20. Yang X, Min X, He W. Sequential development of multifocal recurrent non-Hodgkin's lymphoma of mucosa-associates lymphoid tissue and diffuse large B-Cell lymphoma in a single patient: A case report. *Medicine (Baltimore)* 2018; 97: e10845 [PMID: 29794780 DOI: 10.1097/MD.0000000000010845]

21. Yonal-Hindlerden I, Hindlerden F, Arslan S, Turan-Guzel N, Dogan IO, Nalcaci M. Primary B-Cell Mucosa-Associated Lymphoid Tissue Lymphoma of the Hard Palate and Parotid Gland: Report of One Case and Review of the Literature. *J Clin Med Res* 2016; 8: 824-830 [PMID: 27338485 DOI: 10.14740/jocmr2733v]

22. Shashidara R, Prasad PR, Jaishankar, Joseph T. Follicular lymphoma of the submandibular salivary gland. *J Oral Maxillofac Pathol* 2014; 18: S163-S166 [PMID: 25364171 DOI: 10.4103/0973-9771.141382]

23. Faur A, Lazar E, Cornianu M, Dema A, Lăzăreanu C, Mureșan A, Tăban S. Primary malignant non-Hodgkin's lymphomas of salivary glands. *Rom J Morphol Embryol* 2009; 50: 693-699 [PMID: 19942968]

24. Alves CAF, de Gouveia MM, Queiroz AGDS, Brozoski MA, Otoch JP, de Alcântara PSM, de Lima PP, Felipe-Silva A. Nodular lymphocyte predominance Hodgkin lymphoma of the parotid gland: a case report. *Autops Case Rep* 2012; 2: 43-47 [PMID: 31328651 DOI: 10.4322/acr.2012.007]

25. Revanaappa MM, Sattur AP, Nalkinessar VG, Thakur AR. Disseminated non-Hodgkin's lymphoma presenting as bilateral salivary gland enlargement: a case report. *Imaging Sci in Dentistry* 2013; 43: 59-62 [PMID: 23525854 DOI: 10.5624/isid.2013.43.1.59]

26. Titisindes N, Nikitakis N, Pippire E, Sklavounou A. MALT Lymphoma of Minor Salivary Glands in a Sjögren's Syndrome Patient: A Case Report and Review of Literature. *J Oral Maxillofac Res* 2017; 8: e5 [PMID: 28496965 DOI: 10.5037/jomr.2017.8105]

27. Van Mello NM, Pillen MR, Tak PP, Sankar V. B cell MALT lymphoma diagnosed by labial minor
salivary gland biopsy in patients screened for Sjögren's syndrome. Ann Rheum Dis 2005; 64: 471-473 [PMID: 15708896 DOI: 10.1136/ard.2004.022707]

28 Hew WS, Carey FA, Kernohan NM, Heppleston AD, Jackson R, Jarrett RF. Primary T cell lymphoma of the salivary gland: a report of a case and review of the literature. J Clin Pathol 2002; 55: 61-63 [PMID: 12189237 DOI: 10.1111/jep.55.1.61]

29 Groth RH, van Merkesteyn JP, Bras J. Oral manifestations of non-Hodgkin's lymphoma in HIV-infected patients. Int J Oral Maxillofac Surg 1990; 19: 194-196 [PMID: 2120356 DOI: 10.1016/j.0901-5027(05)80387-x]

30 Beral V, Peterman T, Berkelman R, Jaffe H. AIDS-associated non-Hodgkin lymphoma. Lancet 1991; 337: 805-809 [PMID: 1672901 DOI: 10.1016/0140-6736(91)92513-2]

31 Smedby KE, Ponzoni M. The aetiology of B-cell lymphoid malignancies with a focus on chronic inflammation and infections. J Intern Med 2017; 282: 360-370 [PMID: 28875507 DOI: 10.1111/joim.12684]

32 Pastore C, Gaidano G, Ghia P, Fassone L, Cilia AM, Gloghini A, Capello D, Buonaiuto D, Gonella S, Roncella S, Carbone A, Saglio G. Patterns of cytokine expression in AIDS-related non-Hodgkin's lymphoma. Br J Haematol 1998; 103: 143-149 [PMID: 9792301 DOI: 10.1046/j.1365-2141.1998.00927.x]

33 Oishi N, Bagán JV, Javier K, Zapater E. Head and Neck Lymphomas in HIV Patients: a Clinical Perspective. Int Arch Otorhinolaryngol 2017; 21: 399-407 [PMID: 29018505 DOI: 10.1055/s-0036-1597825]

34 Kikuchi K, Inoue H, Miyazaki Y, Ide F, Kojima M, Kasama K. Epstein-Barr virus (EBV)-associated epithelial and non-epithelial lesions of the oral cavity. Jpn Dent Sci Rev 2017; 53: 95-109 [PMID: 28725300 DOI: 10.1167/jdser.2017.01.002]

35 Grywalska E, Markowicz J, Grabarczyk P, Pasiarski M, Rolinski J. Epstein-Barr virus-associated lymphoproliferative disorders. Postepy Hig Med Dosw (Online) 2013; 67: 481-490 [PMID: 23752600 DOI: 10.5604/17322293.1050999]

36 Hong B, Petrovyan V, Kruger AR. Unusual Presentation of Epstein-Barr Virus-Positive Diffuse Large B-Cell Non-Hodgkin Lymphoma of the Elderly. J Oral Maxillofac Surg 2016; 74: 1180.e1-1180.e7 [PMID: 26850867 DOI: 10.1016/j.joms.2016.01.002]

37 Roschewski M, Wilson WH. EBV-associated lymphomas in adults. Best Pract Res Clin Haematol 2012; 25: 75-89 [PMID: 22409825 DOI: 10.1016/j.beha.2012.01.005]

38 Westmoreland KD, Stanley CC, Montgomery ND, Kaimila B, Kasonkanji E, El-Mallawany NK, Wasswa P, Miete I, Butia M, Ituño S, Chelsa M, Mtunda M, Chikasema M, Mawakwa V, Kampani C, Dhangel BM, Sanders MK, Peterman T, Berkelman R, Jaffe H. AIDS-associated non-Hodgkin lymphoma. J Natl Cancer Inst 2016; 108: 1851-1863 [PMID: 27781390 DOI: 10.1093/jnci/djw26302]

39 Mele A, Pulsoni A, Bianco E, Musto P, Szklo A, Sangaolo MG, Iannitto E, De Renzo A, Martino B, Liso V, Andrizzia C, Pusterla S, Dore F, Maresca M, Rapicetta M, Marcucci F, Mandelli F, Franceschi S. Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood 2003; 102: 996-999 [PMID: 12715414 DOI: 10.1182/blood-2002-10-3230]

40 Carbone A, Gloghini A. Relationships between lymphomas linked to hepatitis C virus infection and their microenvironment. World J Gastroenterol 2013; 19: 7874-7879 [PMID: 23407781 DOI: 10.3748/wjg.v19.i44.7874]

41 Marcucci F, Mele A. Hepatitis viruses and non-Hodgkin lymphoma: epidemiology, mechanisms of tumorigenesis, and therapeutic opportunities. Blood 2011; 117: 1792-1798 [PMID: 20959600 DOI: 10.1182/blood-2010-06-275818]

42 Quinn ER, Chan CH, Hadlock KG, Foung SK, Flint M, Levy S. The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood 2001; 98: 3745-3749 [PMID: 11739181 DOI: 10.1182/blood.v98.13.3745]
production in low grade B cell gastric MALT-type lymphomas stimulated in vitro with Helicobacter pylori. *J Clin Pathol* 1997; **50**: 957-959 [PMID: 9462249 DOI: 10.1136/jcp.50.11.957]

52 *Raderer M*, Streubel B, Wührer S, Häfinger M, Chott A. Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas. *Gut* 2006; **55**: 616-618 [PMID: 16299207 DOI: 10.1136/gut.2005.083022]

53 *Berrebi D*, Lescoeur B, Faye A, Faure C, Vilmer E, Peuchmaur M. MALT lymphoma of lobial minor salivary gland in an immunocompetent child with a gastric Helicobacter pylori infection. *J Paediatr* 1998; **133**: 290-292 [PMID: 9709725 DOI: 10.1016/s0022-3476(98)70239-2]

54 *Georgakopoulou EA*, Achtari MD, Evangelou K, Kittas C. Oral non-Hodgkin's lymphoma in a patient with rheumatoid arthritis treated with etanercept and methotrexate. *J Clin Exp Dent* 2015; **7**: e180-e182 [PMID: 25810835 DOI: 10.4317/jced.51922]

55 *Engels EA*, Cerhan JR, Linet MS, Cosen W, Colt JS, Davis S, Gridley G, Severson RK, Hartge P. Immunorelated conditions and immune-modulating medications as risk factors for non-Hodgkin's lymphoma: a case-control study. *Am J Epidemiol* 2005; **162**: 1153-1161 [PMID: 16253139 DOI: 10.1093/aje/kwi341]

56 *Sène D*, Ismael S, Forien M, Charlotte F, Kaci R, Cacoub P, Diallo A, Dieudé P, Liotti F. Ectopic Germinal Center-Like Structures in Minor Salivary Gland Biopsy Tissue Predict Lymphoma Occurrence in Patients With Primary Sjögren's Syndrome. *Arthritis Rheumatol* 2018; **70**: 1481-1488 [PMID: 29669392 DOI: 10.1002/art.40528]

57 *Zintzaras E*, Voulgarides M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. *Arch Intern Med* 2005; **165**: 2373-2374 [PMID: 16278762 DOI: 10.1001/archinte.165.20.2337]

58 *Voulgaris M*, Ziakas PD, Papageorgiou A, Baimpa E, Tzioufas AG, Moutsopoulos HM. Prognosis and outcome of non-Hodgkin lymphoma in primary Sjögren syndrome. *Medicine (Baltimore)* 2012; **91**: 1-9 [PMID: 22198497 DOI: 10.1097/MD.0b013e18264125c4]

59 *Carubbi F*, Alunno A, Cipriani P, Di Benedetto P, Ruscitti P, Berardicurti O, Bartoloni E, Bistoni O, Catteri S, Ciccia F, Troilo G, Gerli R, Giacomelli R. Is minor salivary gland biopsy more than a diagnostic tool in primary Sjögren's syndrome? Association between clinical, histopathological, and molecular features: a retrospective study. *Semin Arthritis Rheum* 2014; **44**: 314-324 [PMID: 24935529 DOI: 10.1016/j.semarthrit.2014.05.015]

60 *Salomonsson S*, Jonsson MV, Skarstein K, Brokstad KA, Hjelmlström P, Wahren-Herlenius M, Jonsson R. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjögren's syndrome. *Arthritis Rheumat* 2003; **48**: 3187-3201 [PMID: 14613282 DOI: 10.1002/art.13111]

61 *Nocturne G*, Seror R, Fogel O, Belkhir R, Boudaoud S, Sarauz A, Larroche C, Le Guern V, Gottenberg JE, Mariette X. CXCL13 and CCL11 Serum Levels and Lymphoma and Disease Activity in Primary Sjögren's Syndrome. *Arthritis Rheumatol* 2015; **67**: 3226-3233 [PMID: 26359802 DOI: 10.1002/art.39315]

62 *Barnes L*, Myers EN, Prokopakis EP. Primary malignant lymphoma of the parotid gland. *Arch Otolaryngol Head Neck Surg* 1998; **124**: 573-577 [PMID: 9604985 DOI: 10.1001/archotol.124.5.573]

63 *Dey B*, Goyal V, Bharti JN, Mahajan N, Jain S. A rare cytological diagnosis of primary non-Hodgkin's lymphoma of the parotid gland. *J Cytol* 2016; **33**: 108-110 [PMID: 27279690 DOI: 10.4103/0997-9371.182539]

64 *Gadodia A*, Bhalla AS, Sharma R, Thakar A, Parshad R. Bilateral parotid swelling: a radiological review. *Dentomaxillofac Radiol* 2011; **40**: 403-414 [PMID: 21960397 DOI: 10.1259/dmfr/17893787]

65 *Kolokotrinis A*, Konstantinou N, Christakis I, Papadimitriou P, Matiakis A, Zaraboukas T, Antoniades D. Localized B-cell non-Hodgkin's lymphoma of oral cavity and maxillofacial region: a clinical study. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 2005; **99**: 303-310 [PMID: 15716836 DOI: 10.1016/j.tripleo.2004.03.028]

66 *Law NW*, Leader M. Bilateral submandibular gland lymphoma in Sjögren's syndrome. *Postgrad Med J* 1987; **63**: 135-136 [PMID: 3671240 DOI: 10.1136/pgmj.63.736.135]

67 *Terada T*, Primary diffuse large B-cell lymphoma of the submandibular gland. *Int J Exp Clin Exp* 2012; **5**: 179-181 [PMID: 22400062]

68 *Manveen JK*, Subramanym R, Harshaminder G, Madhu S, Narula R. Primary B-cell MALT lymphoma of the parotid: A case report and distinction from benign lymphoid hyperplasia (pseudolymphoma). *J Oral Maxillofac Pathol* 2012; **16**: 97-102 [PMID: 22438648 DOI: 10.4103/0973-029X.92982]

69 *Gadre S*, Ryan MW, Logroño R. MALT lymphoma of the floor of the mouth: a case report. *Ear Nose Throat J* 2009; **88**: E1-E3 [PMID: 19688761]

70 *Zhu L*, Wang P, Yang J, Yu Q. Non-Hodgkin lymphoma involving the parotid gland: CT and MR imaging findings. *Dentomaxillofac Radiol* 2013; **42**: 20130846 [PMID: 23975113 DOI: 10.1259/dmfr.20130846]

71 *King AD*, Lei KI, Ahuja AT. MRI of neck nodes in non-Hodgkin's lymphoma of the head and neck. *Br J Radiol* 2004; **77**: 111-115 [PMID: 15013082 DOI: 10.1259/bjr/53555208]

72 *Dispenza F*, Cicero G, Mortellaro G, Marchese D, Kulamarva G, Dispenza C. Primary non-Hodgkin lymphoma of the parotid gland. *Braz J Orofacial Oral Surg* 2011; **77**: 639-644 [PMID: 22030974 DOI: 10.1590/1808-86942011005000107]

73 *Shalley S*, Chand N, Aggarwal A, Garg LN, Yadav V, Yadav A. Diagnostic Accuracy of Fine Needle Aspiration Cytology in Lesions of Oral Cavity and Salivary Glands: A Clinico-pathological Study. *Open Dent J* 2018; **12**: 782-790 [PMID: 30369988 DOI: 10.2174/1745079018614010782]

74 *Nas S*, Hashmi AA, Khushid A, Fariid N, Edhi MM, Kamal A, Khan M. Diagnostic role of fine needle aspiration cytology (FNAC) in the evaluation of salivary gland swelling: an institutional experience. *BMJ Res Notes* 2015; **8**: 101 [PMID: 25879702 DOI: 10.1186/s13104-015-1048-5]

75 *Fakhry N*, Antonini E, Michel J, Penicaud M, Mancini J, Lagier A, Santini L, Turner F, Christiana MA, Zanaret M, Dussi P, Giovanni A. Fine-needle aspiration cytology in the management of parotid masses: evaluation of 249 patients. *Ear Ann Orofacial Oral Surg Head Neck Dis* 2012; **129**: 131-135 [PMID: 22626640 DOI: 10.1016/j.amer.2011.10.009]

76 *P A C A*, Malsalmani S, Jonathan S. Diagnosis of Salivary Gland Lesions By Fine Needle Aspiration
Cytology and Its Histopathological Correlation in A Tertiary Care Center of Southern India. J Clin Diagn Res 2015; 9: EC07-EC10 [PMID: 26266126 DOI: 10.3760/JCDR.2015.14229.6076]

77 Weiler-Sagie M, Bushlev O, Epelbaum R, Dann EJ, Haim N, Avivi I, Ben-Elak R, Ben-Arie Y, Bar-Shalom R, Israel O. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med 2010; 51: 25-30 [PMID: 20090972 DOI: 10.2967/jnumed.109.067892]

78 Latifoltojar A, Punwani S, Lopes A, Humphries PD, Kussmann M, Menezes LJ, Daw S, Shankar A, Neriman D, Fitzke H, Clifton-Hadley L, Smith P, Taylor SA. Whole-body MRI for staging and interim response monitoring in paediatric and adolescent Hodgkin's lymphoma: a comparison with multi-modality reference standard including (18)F-FDG-PET-CT. Eur Radiol 2019; 29: 202-212 [PMID: 29948084 DOI: 10.1007/s00330-018-5445-8]

79 Wang D, Hao Y, Chen S, Wang H, Ding Y, Zhu X, Ma C. Whole-body MRI versus (18)F-FDG PET/CT for pretreatment assessment of staging of lymphoma: a meta-analysis. Oncol Targets Ther 2018; 11: 3597-3608 [PMID: 29950864 DOI: 10.2147/OTT.S148189]

80 Keraen J, Blanc E, Besson FL, Leguem V, Meyer C, Henry J, Belkhir R, Nocturne G, Mariette X, Seror R. Usefulness of 18F-Fluorodeoxyglucose-Positron Emission Tomography for the Diagnosis of Lymphoma in Primary Sjögren's Syndrome. Arthritis Rheumatol 2019; 71: 1147-1157 [PMID: 30615273 DOI: 10.1002/art.40829]

81 Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaudard P, Reyes F, Lederlin P, Gisselbrecht C. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242 [PMID: 11807147 DOI: 10.1056/NEJMoa011795]

82 Coiffier B. State-of-the-art therapeutics: diffuse large B-cell lymphoma. J Clin Oncol 2005; 23: 6387-6393 [PMID: 16155024 DOI: 10.1200/JCO.2005.05.015]

83 Wilson WH, Gutierrez M, O'Connor P, Frankel S, Jaife E, Chabner BA, Grossbard ML. The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R. Oncol 2002; 29: 41-47 [PMID: 11842388]

84 Yahalom J, Ildidge T, Specht L, Hoppe RT, Li YX, Tsang R, Wirth A. International Lymphoma Radiation Oncology Group, Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys 2015; 92: 11-31 [PMID: 25863750 DOI: 10.1016/j.ijrobp.2015.01.009]

85 Lowry L, Smith P, Qian W, Falk S, Benstead K, Ildidge T, Linch D, Robinson M, Jack A, Hoskin P. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol 2011; 100: 86-92 [PMID: 21664710 DOI: 10.1016/j.radonc.2011.05.013]

86 Armitage JO, Gascoyne RD, Lunning MA, Cavalli F. Non-Hodgkin lymphoma. Lancet 2017; 390: 298-310 [PMID: 28153382 DOI: 10.1016/S0140-6736(16)32407-2]

87 Teckie S, Qi S, Lovic S, Navarrett S, Hsu M, Noy A, Portlock C, Yahalom J. Long-term outcomes and patterns of relapse of early-stage extranodal marginal zone lymphoma treated with radiation therapy with curative intent. Int J Radiat Oncol Biol Phys 2015; 92: 130-137 [PMID: 25863760 DOI: 10.1016/j.ijrobp.2015.01.040]

88 Armitage JO, Longo DL. Is watch and wait still acceptable for patients with low-grade follicular lymphoma? Blood 2016; 127: 2804-2808 [PMID: 26994147 DOI: 10.1182/blood-2015-11-632745]

89 Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, Kofahl-Krause D, Heil G, Welslau M, Balser C, Kaiser U, Weidmann E, Dürk H, Ballo H, Stauch M, Roller F, Barth J, Hoezler D, Hinke A, Brugger W. Study group indolent Lymphomas (StiL). Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381: 1203-1210 [PMID: 23433739 DOI: 10.1016/S0140-6736(12)61763-2]

90 Greb A, Bohlius J, Schiefer D, Schwarzer G, Schulz H, Engert A. High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adults. Cochrane Database Syst Rev 2008; CD004024 [PMID: 18254036 DOI: 10.1002/14651858.CD004024.pub2]

91 Zinzani PL, Tani M, Stefoni V, Albertini P, B podani M, Gherlinzoni F, Alinari L, Vigna E, Terra S. Efficacy of vinorelbine, epurubicin and prednisone combination regimen in pretreated elderly patients with aggressive non-Hodgkin's lymphoma. Haematologica 2001; 86: 287-290 [PMID: 11255276]

92 Parvez A, Tau N, Hussey D, Maganti M, Metser U. (18)F-FDG PET/CT metabolic tumor parameters and radiomics features in aggressive non-Hodgkin's lymphoma as predictors of treatment outcome and survival. Ann Nucl Med 2018; 32: 410-416 [PMID: 29754276 DOI: 10.1007/s12149-018-1260-1]
